-+ 0.00%
-+ 0.00%
-+ 0.00%

Mirum's brelovitug meets primary endpoint in Phase 3 hepatitis delta trial

PUBT·11/10/2026 12:32:16
Listen to the news
Mirum's brelovitug meets primary endpoint in Phase 3 hepatitis delta trial
  • Mirum Pharmaceuticals’ brelovitug met the primary endpoint in its second pivotal Phase 3 trial for chronic hepatitis delta, improving viral response and liver inflammation.
  • No new safety signals emerged in AZURE-4; full results will be presented at an upcoming medical congress.
  • Longer-term Phase 2 results presented at The Liver Meeting showed deepening treatment responses, including in patients with cirrhosis.
  • A U.S. biologics license application is planned for the first half of 2027, with a potential fourth-quarter launch that year, pending approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611100730BIZWIRE_USPR_____20261110_BW113586) on November 10, 2026, and is solely responsible for the information contained therein.